Division of Medical Oncology and Pathology, University of Colorado Denver, Aurora, CO 80045, USA.
J Thorac Oncol. 2012 Jun;7(6):947-53. doi: 10.1097/JTO.0b013e31825581bd.
Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that functions as a key regulatory protein in normal cell growth, survival, metabolism, development, and angiogenic pathways. Deregulation of these processes is a required hallmark of cancer, and dysregulation of mTOR signaling frequently occurs in a wide variety of malignancies, including lung cancer. Targeting of mTOR is thus an attractive strategy in the development of therapeutic agents against lung cancer. In this review, the mTOR-signaling pathway is described, highlighting opportunities for therapeutic intervention and biomarker analysis, and clinical trials in lung cancer including both non-small cell lung cancer and small cell lung cancer.
哺乳动物雷帕霉素靶蛋白（mTOR）是一种丝氨酸/苏氨酸激酶，作为正常细胞生长、存活、代谢、发育和血管生成途径的关键调节蛋白发挥作用。这些过程的失调是癌症的一个必要特征，mTOR 信号的失调经常发生在各种恶性肿瘤中，包括肺癌。因此，针对 mTOR 的靶向治疗是开发治疗肺癌的药物的一种有吸引力的策略。在这篇综述中，描述了 mTOR 信号通路，突出了治疗干预和生物标志物分析的机会，并介绍了肺癌的临床试验，包括非小细胞肺癌和小细胞肺癌。
